Ascendis wins U.S. approval for therapy for children with dwarfism

BioMarin Pharmaceutical

27/02/2026 23:01

Feb 27  (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's A71.F once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.

 (Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Tasim Zahid)

 ((Sahil.Pandey@thomsonreuters.com;))